Approval · Notice of Compliance 14409 · 2013
XTANDI: Notice of Compliance 14409
Issued May 29, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14409
- Date
- May 29, 2013
- Company
- Astellas Pharma Canada IncMarkham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
- Therapeutic class
- Antineoplastic endocrine therapy
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| XTANDI | 02407329 | Marketed |
Medicinal ingredients
- ENZALUTAMIDE 40 MG per CAP